Redx Pharma: ESMO 2021: RXC004 monotherapy Phase I study results
Redx Pharma has two in-house clinical programmes, of which RXC004, a Porcupine inhibitor, is poised to start Phase II trials. Data from the Phase I monotherapy study were presented at ESMO showing RXC004 to be safe and well tolerated at doses up to 2mg. Treatment related adverse events were dose-related and in line with the “on-target” effects of Porcupine inhibition. While the 25 patients studied were not genetically selected, there were encouraging signs of stable disease in those with Wnt ligand driven tumours, with five of seven such patients showing durable stable disease. The Phase II programme will evaluate activity in Wnt ligand driven tumours in pancreatic, biliary, and MSS metastatic colorectal cancers. Redx’s last reported cash of £39.9m provides funding through to end-2022, covering several important value inflection points. Our current rNPV-based valuation is £350.7m, equivalent to 128p/share (86p fully diluted).Redx Pharma is engaged in drug discovery, pre-clinical development and licensing. The principal activities of the business are the discovery and development of proprietary, small molecule drugs to address areas of high, unmet medical need. Co. is developing a porcupine inhibitor drug candidate, RXC004, as a cancer treatment using in vivo models of pancreatic and gastric cancer. ROCK1/2 inhibitors (known as systemic pan-Rock inhibitors) are known to induce hypotension. Co.'s ROCK inhibitor is designed to only work at the site of action in the gastrointestinal tract and degrades quickly, once absorbed, through enzyme-mediated metabolism in the blood, deeming it a soft inhibitor.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.